Compare MKTW & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKTW | CELU |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 34.5M |
| IPO Year | N/A | N/A |
| Metric | MKTW | CELU |
|---|---|---|
| Price | $16.38 | $1.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $20.00 | $6.00 |
| AVG Volume (30 Days) | 8.5K | ★ 44.8K |
| Earning Date | 02-27-2026 | 11-14-2025 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | ★ $342,206,000.00 | $40,578,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | $6.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.08 | $1.00 |
| 52 Week High | $21.74 | $4.35 |
| Indicator | MKTW | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 40.81 |
| Support Level | $16.37 | $1.22 |
| Resistance Level | $16.28 | $1.32 |
| Average True Range (ATR) | 0.51 | 0.08 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 70.00 | 18.94 |
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.